 | • レポートコード：TPM-C02162 • 出版社/出版日：Transparency Market Research / 2018年11月19日 • レポート形態：英文、PDF、170ページ • 納品方法：Eメール • 産業分類：Pharmaceutical |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、T細胞急性リンパ芽球性白血病の世界市場について調べ、T細胞急性リンパ芽球性白血病の世界規模、市場動向、市場環境、治療別（化学療法、放射線療法、骨髄移植、標的療法、免疫療法）分析、エンドユーザー別（病院、診療所、その他）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・T細胞急性リンパ芽球性白血病の世界市場動向 ・T細胞急性リンパ芽球性白血病の世界市場環境 ・T細胞急性リンパ芽球性白血病の世界市場規模 ・T細胞急性リンパ芽球性白血病の世界市場規模：治療別（化学療法、放射線療法、骨髄移植、標的療法、免疫療法） ・T細胞急性リンパ芽球性白血病の世界市場規模：エンドユーザー別（病院、診療所、その他） ・T細胞急性リンパ芽球性白血病の世界市場：地域別市場規模・分析 ・T細胞急性リンパ芽球性白血病の北米市場規模・予測 ・T細胞急性リンパ芽球性白血病のアメリカ市場規模・予測 ・T細胞急性リンパ芽球性白血病の中南米市場規模・予測 ・T細胞急性リンパ芽球性白血病のヨーロッパ市場規模・予測 ・T細胞急性リンパ芽球性白血病のアジア市場規模・予測 ・T細胞急性リンパ芽球性白血病の日本市場規模・予測 ・T細胞急性リンパ芽球性白血病の中国市場規模・予測 ・T細胞急性リンパ芽球性白血病のインド市場規模・予測 ・T細胞急性リンパ芽球性白血病の中東市場規模・予測 ・T細胞急性リンパ芽球性白血病のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Global T-cell Acute Lymphoblastic Leukemia Market: Overview
This report analyzes the current and future scenario of the global T-cell acute lymphoblastic leukemia market. Increase in patient population with T-cell acute lymphoblastic leukemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.
The global T-cell acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global T-cell acute lymphoblastic leukemia market.
Global T-cell Acute Lymphoblastic Leukemia Market: Key Segments
Based on treatment, the global T-cell acute lymphoblastic leukemia market has been segmented into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of T-cell acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been classified into hospital, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global T-cell Acute Lymphoblastic Leukemia Market: Regional Outlook
In terms of region, the global T-cell acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global T-cell acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., and Celgene Corporation.
The global T-cell acute lymphoblastic leukemia market has been segmented as below:
Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
Chemotherapy
Radiation Therapy
Bone Marrow Transplant
Targeted Therapy
Immunotherapy
Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
Hospitals
Clinics
Others
Global T-cell Acute Lymphoblastic Leukemia Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market
4. Market Overview
4.1. Introduction
4.2. Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
4.3. Global T-cell Acute Lymphoblastic Leukemia Market Outlook
4.4. Key Industry Developments
4.5. T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
4.6. Nelarabine: Clinical Trial
4.7. Acute Lymphocytic Leukemia New Cases, 2017
4.8. Reimbursement Scenario for Cancer Treatment
4.9. Regulatory Guidelines for Therapeutics
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends
6. Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment
6.1. Introduction
6.2. Global T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
6.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Bone Marrow Transplant
6.3.4. Targeted Therapy
6.3.4. Immunotherapy
7. Global T-cell Acute Lymphoblastic Leukemia Market, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
7.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by End-user
7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End-user
7.5.1. Hospitals
7.5.2. Clinics
7.5.3. Others
7.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
8. T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region
8.1. Key Findings
8.2. Global Market Scenario
8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
8.4. Global T-cell Acute Lymphoblastic Leukemia Market Forecast, by Region
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East & Africa
8.5. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region
9. North America T-cell Acute Lymphoblastic Leukemia Market
9.1. Key Findings
9.2. North America T-cell Acute Lymphoblastic Leukemia Market Overview
9.3. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
9.4. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
9.6. North America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
9.6.1. Chemotherapy
9.6.2. Radiation Therapy
9.6.3. Bone Marrow Transplant
9.6.4. Targeted Therapy
9.6.4. Immunotherapy
9.7. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
9.8. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
9.8.1. Hospitals
9.8.2. Clinics
9.8.3. Others
9.9. North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
10. Europe T-cell Acute Lymphoblastic Leukemia Market
10.1. Key Findings
10.2. Europe T-cell Acute Lymphoblastic Leukemia Market Overview
10.3. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
10.4. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
10.6. Europe T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
10.6.1. Chemotherapy
10.6.2. Radiation Therapy
10.6.3. Bone Marrow Transplant
10.6.4. Targeted Therapy
10.6.4. Immunotherapy
10.7. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
10.8. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
10.8.1. Hospitals
10.8.2. Clinics
10.8.3. Others
10.9. Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
11. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market
11.1. Key Findings
11.2. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Overview
11.3. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
11.4. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
11.6. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
11.6.1. Chemotherapy
11.6.2. Radiation Therapy
11.6.3. Bone Marrow Transplant
11.6.4. Targeted Therapy
11.6.4. Immunotherapy
11.7. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
11.8. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
11.8.1. Hospitals
11.8.2. Clinics
11.8.3. Others
11.9. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
12. Latin America T-cell Acute Lymphoblastic Leukemia Market
12.1. Key Findings
12.2. Latin America T-cell Acute Lymphoblastic Leukemia Market Overview
12.3. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
12.4. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
12.6. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
12.6.1. Chemotherapy
12.6.2. Radiation Therapy
12.6.3. Bone Marrow Transplant
12.6.4. Targeted Therapy
12.6.4. Immunotherapy
12.7. Latin America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
12.8. Latin America T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
12.8.1. Hospitals
12.8.2. Clinics
12.8.3. Others
12.9. Latin America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market
13.1. Key Findings
13.2. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Overview
13.3. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
13.4. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
13.6. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
13.6.1. Chemotherapy
13.6.2. Radiation Therapy
13.6.3. Bone Marrow Transplant
13.6.4. Targeted Therapy
13.6.4. Immunotherapy
13.7. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
13.8. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, End-user
13.8.1. Hospitals
13.8.2. Clinics
13.8.3. Others
13.9. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2017)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. F. Hoffmann-La Roche Ltd.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Erytech Pharma Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Celgene Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
Table 01: T-cell Acute Lymphoblastic Leukemia Market: Pipeline Analysis
Table 02: Nelarabine: Clinical Trial
Table 03: Authorities Responsible for Reimbursement of Medicines in European Region, 2017
Table 04: Major Regulatory Agencies Responsible for Granting Marketing Authorization for Drugs
Table 05: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 06: Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 07: Global T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 08: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
Table 09: North America T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 10: North America T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 11: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 12: Europe T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 13: Europe T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 14: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 15: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 16: Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 17: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 19: Latin America T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 20: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 21: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Size Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 22: Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 23: Products Offered (Pfizer, Inc.)
Table 24: Products Offered (Novartis AG)
Table 25: Products Offered (F. Hoffmann-La Roche Ltd.)
Table 26: Products Offered (Sanofi)
Table 27: Products Offered (Erytech Pharma, Inc.)
Table 28: Products Offered (Celgene Corporation)